预约演示
更新于：2026-08-23
Levothyroxine Sodium
左甲状腺素钠
更新于：2026-08-23
概要
基本信息
简介左旋甲状腺素钠是一种小分子药物，作用于甲状腺激素受体，是甲状腺激素受体的激动剂。左旋甲状腺素钠可以调节人体新陈代谢，用于治疗垂体前叶功能亢进、甲状腺功能亢进、甲状腺肿、甲状腺功能减退等多种疾病。其作用机制是增加甲状腺激素的水平，从而调节人体的新陈代谢、心血管系统、中枢神经系统等方面的功能。左旋甲状腺素钠是由AbbVie公司开发的，并于1964年8月7日首次获得批准。 |
药物类型 小分子化药 |
别名 Levothyroxine Sodium Hydrate、LT4、Sustained-release levothyroxine sodium + [33] |
靶点 |
作用方式 激动剂 |
作用机制 THR激动剂(甲状腺激素受体激动剂) |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1964-08-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H21I4NNaO9 |
InChIKeyJMLVQURZUYFALV-QWPJCUCISA-N |
CAS号6106-07-6 |
关联
356
项与 左甲状腺素钠 相关的临床试验NCT06790589
COmparison of Two Alternative Thyrotropin Suppression Strategies Among Patients With Advanced Differentiated Cancer of the tHyroid
NCT07424183
T4/T3 Therapy in Hypothyroidism
NCT07697118
A Phase I/II Open-label, Non-randomized, Monocentric, Single-arm Study Evaluating the Safety and Efficacy of Induced CD4+ Treg by LV Vector Transduction Expressing the FOXP3 cDNA (FOXP3-T4) in Patients With IPEX Syndrome
100 项与 左甲状腺素钠 相关的临床结果
登录后查看更多信息
100 项与 左甲状腺素钠 相关的转化医学
登录后查看更多信息
100 项与 左甲状腺素钠 相关的专利（医药）
登录后查看更多信息
41,215
项与 左甲状腺素钠 相关的文献（医药）2026-12-01JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
Virtual screening of compounds for the development of thyroid hormone analogues for potential application in cardiac regeneration
Article
作者: de Oliveira Filho, José de Anchieta ; de Morais Gomes, Enéas Ricardo ; Pascutti, Pedro Geraldo ; Chaves, Elton José Ferreira
Abstract:
Cardiovascular diseases remain the leading global cause of mortality, largely due to the limited regenerative capacity of adult cardiac tissue. Thyroid hormones, particularly tri-iodothyronine (T3), have been shown to stimulate cardiomyocyte proliferation through activation of the thyroid hormone receptor alpha (TRα), making this receptor a promising therapeutic target. Here we report a hierarchical and consensus, multi-level virtual screening pipeline integrating Molecular Mechanics (MM), Quantum Mechanics (QM), hybrid QM/MM calculations, and reactivity analysis based on the Fukui function to identify novel TRα agonists. Starting from 412 million compounds in the ZINC15 database, physicochemical filtering, validated pharmacophore matching, and docking guided by ROC curve optimization yielded 568 candidates, from which eight compounds were selected through chemically guided visual inspection. Binding affinity was evaluated with MD/MM-PBSA, PM7, and QM/MM (B3LYP/6-31G*/CHARMM36), and complemented by Fukui reactivity mapping to rationalize protein–ligand recognition. Two ligands, including the approved drug Cetraxate, consistently showed favorable interaction energies and reactivity patterns comparable to T3, suggesting agonistic potential. This work provides a rigorous, multi-scale computational framework and identifies two mechanistically supported TRα agonist candidates for future experimental validation in cardiac regeneration.
2026-11-01TALANTA
Biocompatible folic acid-chitosan-coated gold nanorods as a dual-mode aptasensing platform for thyroxine detection
Article
作者: Kumar, Suman ; Jha, Niki S
Thyroxine is the primary thyroid hormone (TH) regulated by thyrotropin-releasing hormone (TRH). This study demonstrates the detection of thyroxine (T4) using an aptamer-based dual-modality platform constructed with folic acid-chitosan-conjugated gold nanorods (FACS-AuNR). FACS-AuNR functions as a reversible and highly specific optical probe, translating aptamer-analyte recognition into quantifiable fluorescence changes via an ON-OFF-ON signal in the presence of aptamer and thyroxine. The probe demonstrated a limit of detection of 1.89 ± 0.41 nM for T4. The electrochemical behaviour of the probe-aptamer on glassy carbon electrode (GCE) (Apt@FCCS-AuNR@GCE) was evaluated by cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) in the presence of the external redox probe [Fe(CN)6]4-. Under optimal conditions at pH 4.0, the limit of detection for T4 was determined to be 6.47 ± 0.13 pM within the 10-100 pM range by differential pulse voltammetry (DPV). Furthermore, the practical applicability of Apt@FCCS-AuNR@GCE was demonstrated for the detection of commercially available thyroxine tablets in serum samples.
2026-10-01POULTRY SCIENCE
Efficacy of dietary onion powder (Allium cepa L.) as a phytogenic feed additive: Effects on growth performance, blood biochemistry, gut morphology, and immune function in broiler chickens
Article
作者: Farooq, U ; Yu, Yue ; Zhong, Qiu ; Rahman, S ; Akhtar, R ; Abbas, G ; Fouad, Dalia ; Bughio, E ; Khan, S ; Iqbal, Z M ; Raziq, F ; Han, Yuwen ; Khan, M T
A study was carried out to evaluate the impact of dietary onion powder (OP) on growth performance, serum biochemistry, gut morphology, and immune response in broiler chickens. A total of 320 day-old chicks each with a uniform initial body weight of 42.50 ± 0.40 g were raised in an open-sided shed for six weeks using a completely randomized design. Birds were weighed and randomly divided into four treatment groups. Each group was replicated five times with 16 chicks each. The dietary treatments included: T₁ (basal diet), T₂ (OP at 3 g/kg feed), T3 (OP at 3.5 g/kg feed), and T4 (OP at 4 g/kg feed). Growth performance parameters, serum biochemical indices, intestinal histomorphology, and immune response traits were evaluated across all groups. Results demonstrated that OP supplementation significantly (P= 0.0001) improved growth performance. Cumulative feed intake and body weight gain increased in a dose-dependent manner, with the highest values recorded in the highest supplementation group (T4). Feed conversion ratio was also significantly improved, while mortality remained unaffected across all treatments (P= 0.640). Intestinal histomorphology was markedly enhanced, as OP increased villus height and villus height-to-crypt depth ratio, while reducing crypt depth, with the most pronounced effects observed in T4. Hematological indices, including red blood cells, white blood cells, hemoglobin, and packed cell volume, remained statistically unchanged (P> 0.05). Serum biochemical analysis revealed significant improvements (P< 0.05) in lipid and metabolic profiles, with reductions in cholesterol, triglycerides, glucose, and low-density lipoprotein, alongside increased high-density lipoprotein levels in OP-supplemented groups, particularly at higher OP-supplemented groups. Furthermore, humoral immune responses were significantly enhanced, with higher antibody titers against Newcastle Disease and Infectious Bronchitis. Dietary supplementation of onion powder, particularly at higher inclusion levels, effectively enhances growth performance, intestinal health, metabolic profile, and immune competence in broiler chickens without adversely affecting hematological stability. These findings suggest that onion powder can serve as a natural growth-promoting and health-enhancing feed additive in poultry production systems.
100 项与 左甲状腺素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳头状及滤泡状癌 | 加拿大 | 2026-05-25 | |
| 乳头状甲状腺癌 | 加拿大 | 2026-05-25 | |
| 分化型甲状腺癌 | 美国 | 2022-04-29 | |
| 粘液性水肿昏迷 | 美国 | 2011-06-24 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 甲状腺功能亢进症 | 中国 | 2000-01-01 | |
| 甲状腺癌 | 中国 | 2000-01-01 | |
| 甲状腺肿 | 日本 | 1998-02-12 | |
| 先天性甲状腺功能减退症 | 韩国 | 1974-04-06 | |
| 粘液水肿 | 韩国 | 1974-04-06 | |
| 甲状腺功能减退症 | 日本 | 1964-08-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 内分泌与代谢疾病 | 临床前 | 美国 | 2019-08-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 34 | (Treatment) | 顧艱網積築鬱壓繭簾窪(膚鑰窪鹹艱築衊選觸艱) = 醖製夢壓餘膚選齋顧網 顧糧選夢範簾餘蓋簾淵 (網願憲觸網網鹽蓋鹹積, 1.469) 更多 | - | 2026-05-29 | ||
(Control) | 顧艱網積築鬱壓繭簾窪(膚鑰窪鹹艱築衊選觸艱) = 膚壓鑰憲繭範艱鬱簾蓋 顧糧選夢範簾餘蓋簾淵 (網願憲觸網網鹽蓋鹹積, 1.127) 更多 | ||||||
临床2期 | 45 | 夢積顧蓋築憲糧顧繭襯(艱積獵蓋襯網願願壓鬱) = The only notable adverse event was rib fractures in a placebo group participant (TSH 3.04 mIU/L at 6 months). Two participants in the placebo group restarted levothyroxine (n = 1, TSH > 10 mIU/L; n = 1, fatigue). 積醖遞醖顧蓋鑰積淵選 (鹽膚築繭顧糧鬱憲築鹽 ) | 积极 | 2025-07-30 | |||
Placebo | |||||||
N/A | 1 | 夢遞鏇範鹽衊鹹鬱鹽築(網築夢遞艱構積壓蓋餘) = 艱餘衊壓網觸鹽艱窪夢 顧網衊遞餘構鬱遞選蓋 (餘獵網淵齋鹽壓鹹鏇夢 ) 更多 | 积极 | 2025-07-12 | |||
临床2期 | 46 | 蓋築鏇蓋選構艱網觸構(糧醖觸糧鏇鑰鑰夢獵顧) = 構窪壓蓋齋壓醖壓簾獵 積壓鏇襯齋簾築遞鏇蓋 (鏇遞範積構壓構廠願顧, 醖鑰鹹糧餘醖製衊簾鹽 ~ 糧窪鑰艱齋餘鏇繭醖製) 更多 | - | 2025-07-03 | |||
N/A | 203 | 憲製願壓鑰衊網築餘鏇(憲淵遞憲糧製顧壓簾憲) = 醖顧窪淵範淵範齋餘繭 餘獵鹹鹹觸鹹製選齋顧 (淵鬱襯選顧獵選鹹窪觸 ) 更多 | 积极 | 2025-05-14 | |||
Enteral levothyroxine | 餘憲糧壓遞蓋醖夢糧襯(範積膚遞廠憲齋醖網積) = 鹹構築遞糧鑰鏇淵膚襯 遞觸壓構廠網鏇積襯憲 (壓艱衊鬱糧糧衊鏇構壓 ) | ||||||
N/A | iodine metabolism status assessed by urinary iodine excretion | 150 | Prophylactic LT4 treatment | 遞網廠夢衊網顧壓淵鹹(鑰遞鹹網憲鬱顧築衊觸) = 願觸鬱齋醖蓋窪觸醖鹹 衊齋廠糧獵齋鹹蓋淵夢 (蓋鹹鬱糧鹹廠廠襯窪淵 ) | 积极 | 2025-01-01 | |
No LT4 treatment | 遞網廠夢衊網顧壓淵鹹(鑰遞鹹網憲鬱顧築衊觸) = 夢簾醖齋夢夢願觸鬱淵 衊齋廠糧獵齋鹹蓋淵夢 (蓋鹹鬱糧鹹廠廠襯窪淵 ) | ||||||
临床2期 | 13 | Placebo+Levothyroxine (Single Therapy) | 醖鬱願遞壓鹹獵觸憲構(築顧觸蓋範選遞製鹽願) = 鏇製鹽鑰範窪憲鹹憲願 壓遞鏇憲簾鹹鹽遞蓋壓 (鹽繭製觸範鏇願鑰壓餘, 3.9) 更多 | - | 2024-06-14 | ||
(Combination Therapy) | 醖鬱願遞壓鹹獵觸憲構(築顧觸蓋範選遞製鹽願) = 壓遞鹹鏇鏇蓋醖製顧醖 壓遞鏇憲簾鹹鹽遞蓋壓 (鹽繭製觸範鏇願鑰壓餘, 2.1) 更多 | ||||||
临床2期 | 46 | 鑰艱積遞鬱願鹹醖窪襯(製憲遞製積範製築襯壓) = 獵鹹艱淵獵憲襯憲餘淵 鬱繭蓋夢膚遞選繭餘選 (鬱蓋製鬱獵壓選構壓網 ) | 积极 | 2024-05-30 | |||
临床3期 | 838 | (Thyroxine) | 築夢鏇窪餘夢簾鏇鏇遞 = 築顧鏇鹽築鏇範鹽願膚 遞餘網繭鹹鏇顧網艱繭 (簾艱簾夢淵願壓蓋鑰顧, 繭憲淵夢醖積願範積繭 ~ 願衊蓋鬱觸範艱憲遞築) 更多 | - | 2024-01-10 | ||
(Saline Placebo) | 築夢鏇窪餘夢簾鏇鏇遞 = 窪憲衊淵襯夢糧廠鑰顧 遞餘網繭鹹鏇顧網艱繭 (簾艱簾夢淵願壓蓋鑰顧, 鑰鏇醖齋鏇蓋糧獵繭築 ~ 糧齋鏇網窪鹽窪鹹選窪) 更多 | ||||||
临床4期 | serum thyrotropin (TSH) | free thyroxine (fT4) | total thyroxine (TT4) ... 更多 | - | 艱觸窪鬱選憲鑰築製繭(襯鏇醖鹹選蓋餘襯鏇鹹) = 選淵壓鹹淵遞願艱範鬱 遞淵觸觸衊鹽窪觸醖窪 (構簾獵鬱網願鹽顧鹹築 ) 更多 | 积极 | 2023-12-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用